The potential risks of expedited approval of drugs for acute bacterial infections

JAMA Intern Med. 2014 Sep;174(9):1436-7. doi: 10.1001/jamainternmed.2014.3055.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Acute Disease
  • Anti-Bacterial Agents / therapeutic use*
  • Bacterial Infections / drug therapy*
  • Clinical Trials as Topic
  • Drug Approval*
  • Drug Resistance, Bacterial
  • Humans
  • Research Design
  • United States
  • United States Food and Drug Administration


  • Anti-Bacterial Agents